KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Research & Development (2016 - 2025)

Historic Research & Development for CareDx (CDNA) over the last 13 years, with Q3 2025 value amounting to $16.8 million.

  • CareDx's Research & Development fell 410.04% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year decrease of 745.36%. This contributed to the annual value of $72.4 million for FY2024, which is 1155.67% down from last year.
  • Latest data reveals that CareDx reported Research & Development of $16.8 million as of Q3 2025, which was down 410.04% from $16.8 million recorded in Q2 2025.
  • Over the past 5 years, CareDx's Research & Development peaked at $24.4 million during Q1 2023, and registered a low of $16.0 million during Q1 2021.
  • Over the past 5 years, CareDx's median Research & Development value was $19.0 million (recorded in 2021), while the average stood at $19.6 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 6544.84% in 2021, then tumbled by 2318.02% in 2024.
  • CareDx's Research & Development (Quarter) stood at $22.0 million in 2021, then increased by 6.91% to $23.6 million in 2022, then dropped by 22.46% to $18.3 million in 2023, then decreased by 9.64% to $16.5 million in 2024, then increased by 1.54% to $16.8 million in 2025.
  • Its last three reported values are $16.8 million in Q3 2025, $16.8 million for Q2 2025, and $18.5 million during Q1 2025.